Modulating the immune response with liposomal delivery

David Nardo, David Henson, Joe E. Springer, Vincent J. Venditto

Research output: Chapter in Book/Report/Conference proceedingChapterpeer-review

4 Scopus citations


Lipid-based nanoparticles (LNPs) provide a platform for drug, gene, and vaccine delivery with clinical applicability to treat a variety of diseases. As advances in drug development and immune mechanisms of disease continue to evolve, LNPs are positioned to have a profound impact on the future of immunomodulatory therapeutics. This chapter offers an overview of the principles of liposomal therapeutics, and the immune system while highlighting the clinically relevant liposomal therapeutics focused on small-molecule drugs, genes, and vaccines. Using the current state of the field of liposomal therapeutics, and the lessons learned from these preclinical and clinical studies, we will be able to pave the way for future advances in clinical liposomal immunomodulation.

Original languageEnglish
Title of host publicationNanomaterials for Clinical Applications
Subtitle of host publicationCase Studies in Nanomedicines
Number of pages53
ISBN (Electronic)9780128167052
StatePublished - Jan 1 2020

Bibliographical note

Publisher Copyright:
© 2020 Elsevier Inc. All rights reserved.


  • Drug delivery
  • gene delivery
  • immune modulation
  • liposome
  • vaccine

ASJC Scopus subject areas

  • General Engineering
  • General Materials Science


Dive into the research topics of 'Modulating the immune response with liposomal delivery'. Together they form a unique fingerprint.

Cite this